Discontinue ViraferonPeg Pen treatment with homicidal ideation
The summary of product characteristics for ViraferonPeg Pen (peginterferon alfa-2b; Merck Sharp & Dohme) now recommends that treatment is discontinued if the patient experiences homicidal ideation. Additionally, pulmonary fibrosis and pulmonary arterial hypertension have been added as adverse events of unknown frequency.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069255
Recommended from Pharmaceutical Press